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Summary of 
Recommendations  
i. A UK-wide paediatric specialist clinical network should be established to 
provide specialist clinical expertise, support discussion of complex cases, 
provide support to clinicians and to assist in evidence generation.    
 
ii. The National Medical Director and Chief Pharmaceutical Officer for England 
will write to doctors and pharmacists reminding them of General Medical 
Council (GMC) guidance on the prescribing and use of unlicensed medicines 
– and to clarify the procedure for prescribing and supplying cannabis-based 
products for medicinal use (CBPMs).  Clinicians will also be made aware of 
how they can access the Health Education England (HEE) cannabis 
education package, commissioned by NHS England, and published 
alongside this report. 
 
iii. NHS England and NHS Improvement and the Department of Health and 
Social Care (DHSC) should work together to develop clear information for 
patients and patient groups on the prescribing of cannabis-based products 
for medicinal use.  
 
iv. The National Institute for Health Research (NIHR) should support research 
into the five priority research areas that have been identified by the draft 
National Institute for Health and Care Excellence (NICE) clinical guideline on 
the use of cannabis-based products for medicinal use.  
 
v. For severe treatment-resistant paediatric epilepsy, evidence generation 
should be in two forms:  
 
- Support one or more randomised control trials (RCTs) using a standardised 
approach with several comparative treatment arms. 
 
- NHS England and NHS Improvement and NIHR in conjunction with the 
specialist network will work together to determine an appropriate alternative 
study design that will enable evidence generation for those patients who 
cannot be enrolled into a standard RCT. This scope of study should include 
those children and young adults who are currently in receipt of a CBPM.  
 
vi. These should commence as soon as possible, pending ethical review, and if 
necessary the alternative study should commence in advance of the RCT.  
 
vii. NHS England and NHS Improvement, DHSC and Devolved Administrations 
should work with industry and academia to scope the development of a 
national UK patient registry to collect a uniform data set, across all 
indications, for patients prescribed a cannabis-based product for medicinal 
use in the United Kingdom. 
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viii. NHS England and NHS Improvement will also explore how to update the 
National Genomic Test Directory so that whole genome sequencing would 
be offered to all children with severe treatment-resistant epilepsy under 
consideration for treatment with medical cannabis. 
 
ix. DHSC and Medicines and Healthcare products Regulatory Agency (MHRA) 
should work to provide access to information on good quality products, 
manufactured to Good Manufacturing Practice standard and with consistent 
ratios of cannabidiol (CBD) to delta-9-Tetrahydrocannabinol (THC) between 
batches.  
 
x. NHS England and NHS Improvement should work with suppliers to ensure 
that sufficient stock of good quality CBPMs are available and that the 
products available offer the best value for the NHS, including scoping options 
for UK manufacture.  
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Background 
 
 
1. On 1st November 2018, cannabis-based products for medicinal use (CBPMs) 
were rescheduled under the Misuse of Drugs Regulations 2001 from 
Schedule 1 to Schedule 2. This change followed advice from the Chief 
Medical Adviser to the UK Government (3rd July 2018) and the Advisory 
Council on the Misuse of Drugs (19th July 2018). Both advised that the 
rescheduling of these products would facilitate the development of clinical 
evidence.   
 
2. Since the change in regulations, subject to local governance arrangements, 
doctors on the Specialist Register of the General Medical Council (GMC) 
have been able to prescribe an unlicensed CBPM if clinically appropriate for 
their patients. In addition, there may be some circumstances in which GPs 
may be asked to prescribe under the direction of a specialist as part of 
shared care arrangements.   
 
3. The government has defined “a cannabis-based product for medicinal use in 
humans” as a preparation or other product, other than one to which 
paragraph 5 of part 1 of Schedule 4 applies, which1—  
 
(a) is or contains cannabis, cannabis resin, cannabinol or a 
cannabinol derivative (not being dronabinol or its stereoisomers);  
(b) is produced for medicinal use in humans; and—  
(c) is—  
(i) a medicinal product, or  
(ii) a substance or preparation for use as an ingredient of, or in the 
production of an ingredient of, a medicinal product;” 
 
4. If the three limbs are met, then the preparation or product is considered as a 
“cannabis-based product for medicinal use in humans” and a Schedule 2 
drug under the 2001 Regulations. 
 
5. Also set out in the legislation are three routes for accessing CBPMs: 
 
• either as a medicine with a marketing authorisation;  
 
• as part of a clinical trial; or 
 
• as a “special” medicine supplied through existing Medicines and 
Healthcare Products Regulatory Agency (MHRA) licensed routes.   
 
6. Cannabis has many active chemical constituents and two of these 
constituents, delta-9-Tetrahydracannabinol (THC) and cannabidiol (CBD) 
have been investigated the most with respect to their medicinal value. THC 
is the major psychoactive constituent of cannabis and is considered 
responsible for giving so called “highs” to users of cannabis. CBD on the 
 
1 Home Office Regulations  
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other hand, is not psychoactive.  Products falling within Schedule 2 contain 
varying quantities and ratios of THC and CBD.   
 
7. Recent data on cannabis use in recreational users (March 2019) is 
consistent with previous evidence suggesting that the use of cannabis with a 
high concentration of THC has harmful effects on mental health2.  Whilst the 
evidence base continues to develop, on balance, the use of high strength 
THC regularly and over the longer term, would appear to put people at 
higher risk of harm.  
 
8. Currently almost all CBPMs prescribed by specialist doctors are unlicensed 
medicines and are therefore prescribed as ‘specials’. This situation will 
remain the case until other products have received a marketing authorisation 
from either the European Medicines Agency or the MHRA.  The MHRA 
defines a ‘special’ as a product which “has been specially manufactured or 
imported to the order of a doctor, dentist, nurse independent prescriber, 
pharmacist independent prescriber or supplementary prescriber for the 
treatment of individual patients”.   
 
9. Unlike licensed medicines, CBPMs have not undergone rigorous tests for 
quality, safety and efficacy. Therefore, local medicines governance 
arrangements will always include robust arrangements to safeguard patients 
where there is a clinical need to use an unlicensed medicine. These 
arrangements will consider the evidence base, and the risks and benefits of 
using the medicine before allowing its use. If necessary, funding 
arrangements are subsequently considered.  
 
10. The exceptions to the above are the cannabis-based products dronabinol, 
Sativex® and nabilone, all of which have been individually rescheduled 
under the Misuse of Drugs Regulations 2001 and have been granted a 
marketing authorisation from the MHRA or equivalent medicines regulatory 
body.  Another product Epidyolex® is currently in the process of being 
considered for a European marketing authorisation.  Epidyolex® is a CBD-
only product which is available through compassionate use and extended 
access programmes prior to licensing.  
 
11. There are other products which are also derived from the cannabis plant that 
were never scheduled as they do not contain controlled substances and 
therefore are not covered by the change in the regulations. An example is 
CBD oils sold through health shops.  These products are classed as food 
supplements and are not sold for medicinal use.  
 
12. Following the rescheduling the Chief Medical Adviser to the UK Government, 
National Medical Director and Chief Pharmaceutical Officer wrote to 
clinicians to set out expectations of what the regulatory change would mean 
in practice for clinicians working in the NHS and in private practice. This 
letter published on 31st October 2018 contained links to the interim clinical 
guidance developed by the Royal College of Physicians (RCP)and the British 
 
2 The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe 
(EU-GEI): a multicentre case-control study. Di Forti, Marta Amoretti, Silvia et al. The Lancet 
Psychiatry, Volume 6, Issue 5, 427 - 436 
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Paediatric Neurology Association (BPNA). Guidance from the Association of 
British Neurologists (ABN) was issued subsequently. Similar letters were 
issued in the Devolved Administrations.  
 
13. A further UK-wide letter was issued. The second letter, published on 20th 
November 2018, clarified the status of the interim clinical guidance, and 
provided further clarification in relation to synthetic cannabinoids for 
medicinal use.  
 
14. Since the change in regulations, there has been an increase in the 
prescribing of CBD products, but there has been no increase in NHS 
prescriptions of THC-containing products:  
 
• 111 patients have accessed Epidyolex® through compassionate use and 
early access programmes ahead of a licensing decision by the European 
Medicines Agency.  
 
• Intelligence from NHS England Controlled Drugs Accountable Officers is 
that, up until the end to March 2019, five patients have had private 
prescriptions issued for a CBPM in an independent secondary/tertiary 
care setting in England.  
 
• According to data from the NHS Business Services Authority (March 
2019) there have been fewer than 10 NHS prescriptions for CBPMs 
issued in primary care since November 2018.   
 
15. The Secretary of State for Health and Social Care met a number of families 
on 19 March 2019 to listen to their concerns about access to CBPMs.  
Following the meeting, he asked NHS England and NHS Improvement to 
review NHS system processes to identify and recommend any action 
necessary to address any barriers to clinically appropriate prescribing on the 
NHS.  
 
16. The review was led by the National Medical Director and the Chief 
Pharmaceutical Officer for England and the focus of the review was severe 
treatment-resistant paediatric epilepsy, as most cases were for this condition 
and it is the condition for which there are the strongest arguments for 
improving access.  Two cases were for chronic neuropathic pain indications 
with other associated conditions.  
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Aims and Objectives 
 
17. The review was aimed at addressing the following question: 
 
• Where they exist, what are the barriers to patients accessing 
cannabis-based products for medicinal use within the NHS where they 
are clinically appropriate for the patient, and how might these barriers 
be overcome? 
 
18. The review sought to:  
 
• identify the potential barriers to the appropriate prescribing of CBPMs;   
 
• identify any changes that would need to be put in place to support 
appropriate prescriptions of CBPMs in future; and 
 
• identify ways to facilitate the building of an evidence base for the use 
of CBPMs.   
 
19. NHS England and NHS Improvement worked with the All-Party 
Parliamentary Group (APPG) on Medical Cannabis under Prescription and 
with patient groups, to identify patient cases which should be included in the 
review. Twenty-one cases were put forward. Twenty cases were reviewed, 
as consent was not received for one case.  Eighteen of the cases were in 
England. A further two patients from Northern Ireland were included at the 
request of the Northern Ireland Executive.  
 
20. The review was undertaken through: 
 
• Face-to-face or telephone meetings with patients and their families 
and/or carers, who were invited to share their experiences and give 
their views; 
 
• Structured interviews with the relevant NHS staff for each case being 
reviewed; and 
 
• A short survey of clinical commissioning groups (CCGs) in each of the 
case study local areas.    
 
21. Key lines of inquiry for the review were developed based on the existing 
process for the prescribing of unlicensed medicines. The key lines of inquiry 
were used to test this process by considering the prescribing decision, the 
commissioning decision and the availability of supply.   
 
22. Terms of Reference for the review are attached at Annex A.  
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Findings and Key Themes  
 
 
Clinical Evidence  
23. The vast majority of the clinicians we spoke to told us that the lack of good 
quality randomised control trial (RCT) data demonstrating adequate safety 
and clinical-cost effectiveness of CBPMs for all indications is a major hurdle 
to prescribing.   
 
24. Most clinicians told us that products containing THC would not be prescribed 
in their trusts, primarily because of the lack of evidence, a lack of knowledge 
about the products and a lack of long-term safety data. Several clinicians 
referenced the higher risk of impaired mental health from longer term 
exposure to THC and the need to proceed with caution.    
 
25. In contrast we heard that RCTs do exist for some CBD-only products and 
because of this, clinicians are using these products for the conditions 
specified in the BPNA guidance, as part of the compassionate or extended 
access schemes.  
 
26. The interviews indicated that clinicians are very cautious in prescribing 
CBPMs due to the lack of any data on efficacy and long-term adverse effects 
in children. However, the interviews suggested a spectrum in clinicians’ 
willingness to prescribe, with some clinicians more willing to prescribe on an 
individual case-by-case basis.  
 
27. We heard clearly from parents and carers that whilst they acknowledge that 
the evidence base is limited, they feel that clinicians are not adequately 
considering the international observational study data.   
 
28. Parents and carers told us that their children are already prescribed several 
other antiepileptic medicines, including some that are off-label or unlicensed, 
many of which have significant adverse effects and that they want a 
cannabis-based medicinal product to be prescribed either in addition to, or 
instead of, existing treatment.  
 
29. Many of the clinicians we interviewed told us that, as with all unlicensed 
medicines, the potential risks of using a CBPM should be assessed against 
the effect of continued seizures (in some cases up to 300 per week) on the 
development of the child.   
 
30. CBPMs are used in a variety of conditions. Parents, carers and clinicians told 
us that there are unique factors in considering the use of CBPMs in cases of 
severe treatment-resistant paediatric epilepsy.    
 
31. We heard that the primary issue is that severe treatment-resistant paediatric 
epilepsy carries with it a risk of sudden death. Dravet syndrome-related 
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mortality is estimated to be around 20%3, with most deaths occurring before 
10 years of age. Sudden unexpected death in epilepsy and status epilepticus 
cause around 80% of deaths in this condition; and in approximately a third of 
cases, patients with epilepsy do not respond to other anti-epileptic 
medicines. We heard that patients with severe treatment-resistant epilepsy 
have typically tried most other licensed medicines, often with little obvious 
benefit and an increased risk of adverse effects.  
 
32. The children included in our review had complex aetiologies and had tried 
multiple combinations of antiepileptic medicines and other treatments (e.g. 
surgery or vagus nerve stimulation) which had limited impact on reducing 
seizure frequency.  Clinicians noted that CBPMs are not a ‘miracle cure’ for 
all patients with severe treatment-resistant epilepsy.  However, when 
patients do respond, there is some observational data showing that CBPMs 
can reduce seizure frequency for some patients leading to better control, 
fewer A&E attendances and a better quality of life for both the patient and 
the family.  
 
Guidance to Support Clinicians 
33. Most of the clinicians we spoke to stated that they found the interim clinical 
guidance drafted by the specialist bodies useful, as it provided a framework 
to work within and outlined the available evidence.   
 
34. However, the interim clinical guidance was cited by all the parents and 
carers as a key barrier to prescribing CBPMs in cases of severe treatment-
resistant paediatric epilepsy. Other patients felt the same. They feel that 
clinicians often stick rigidly to the guidance and are not considering each 
case on an individual basis, as per the GMC guidance on prescribing off-
label or unlicensed medicines.  
 
35. Many clinicians told us that they would not prescribe any product other than 
a pure cannabidiol and that they would not prescribe a CBPM outwith the 
indications of Dravets syndrome and Lennox-Gastaut syndrome. In only a 
few cases did we hear that CBPMs containing THC were considered for the 
patient.  
 
36. Many review meetings with carers and/or families also demonstrated that 
their knowledge of CBPMs is good and continuing to develop. Some carers 
have undertaken extensive research into the properties of CBPMs, the 
limitations and the potential side effects. They have used a variety of 
evidence sources to inform their opinions and have brought that evidence 
with them to discuss with their clinicians. 
 
37. Trust Medical Directors and Chief Pharmacists told us that without the 
necessary evidence base, and given the cost of CBPMs, it was unlikely that 
these medicines would be routinely funded. 
 
 
3 https://www.nice.org.uk/guidance/gid-ta10274/documents/final-scope  
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38. Patients with indications related to neuropathic pain told us they felt that the 
NICE Clinical Guideline 186: Management of Multiple Sclerosis in adults was 
too restrictive as it did not recommend the use of the licensed cannabis-
based medicinal product due to a lack of cost effectiveness data.  
 
39. We consistently heard from all parties that the rapid re-scheduling of CBPMs 
in Autumn 2018 led to a very high expectation from patients and their 
families that they would be able to access these medicines on the NHS.   
 
40. Several patients and their families reported that they have very good 
relationships with their specialist clinicians, especially where they have been 
in the care of a clinician for many years. However, other families and patients 
reported that trying to persuade clinicians and Trusts to prescribe CBPMs, 
both before and after the legislative change, had been very frustrating and 
on occasion led to tension.   
 
41. Clinicians also told us that in some circumstances, these high expectations, 
coupled with a lack of high-quality clinical evidence and no licensed products 
has strained the relationships with families.   
 
42. Clinicians reported that whilst the regulatory change was intended to 
facilitate more research into the use of CBPMs and allow limited access for 
patients based on individual clinical need, there was little time to consider the 
impact on well-established NHS medicines policies, governance systems 
and clinical practice.  
 
43. Many families raised concerns around the lack of involvement in decision-
making. They also told us that information provided by NHS organisations 
was inadequate, particularly in written communications concerning 
governance processes or decisions made relating to CBPMs. In many cases, 
patients thought the explanations given to them for declining to prescribe 
CBPMs were incomplete or insufficient. Patients and their families or carers 
fed back that whilst communications with specialist clinicians are often good, 
the relationship with the NHS Trust was not felt to be open. 
 
 
Cost and Supply 
44. All parties told us that, should the clinician agree that a prescription for a 
CBPM is clinically appropriate, the next key barrier is cost of the product and 
funding. In normal circumstances for unlicensed medicines, NHS Trusts 
would be responsible for identifying funding for individual patients. However, 
in practice, NHS Trusts tend to fund medicines for many indications but 
generally for lower cost products, and for short term use only.   
 
45. Several NHS Trusts have therefore made Individual Funding Requests to 
either their local CCG or NHS England depending on the commissioned 
indication.  
 
46. Some families fed back that due to a lack of clarity around the availability of 
NHS funding or a delay in obtaining it, they have obtained a private 
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prescription, imposing a very considerable and often unsustainable financial 
burden on themselves.   
 
47. Some Trusts are currently funding – or would be willing to fund – CBPMs in 
indications of intractable paediatric epilepsy, but they have told us this is 
unsustainable in the long term, particularly as some specialist NHS Trusts 
may be responsible for the care of several patients over the longer term. In 
several instances, NHS Trusts stressed that whilst funding was a factor in 
their decision making, the lack of clinical evidence for the use of CBPMs was 
the primary determinant of the prescribing decision. 
 
48. As most CBPM products are not manufactured in the UK, the NHS is reliant 
on importing the products. The NHS needs to adhere to the export 
procedures of other countries, which can cause delays and difficulties with 
sourcing the correct product.   
 
49. Pharmacists reported that they have systems in place to import the products 
but raised concerns around the difficulty in knowing which products are of 
good quality and if the batches ordered have consistent ratios of CBD and 
THC (thereby ensuring a standardised dose of each component). 
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Conclusions and 
Recommendations  
Guidance to support clinicians  
 
50. Clinical understanding of CBPMs is variable, and this variability in 
understanding can have an impact on relationships with patients, parents 
and carers.  
 
51. The complexity of the cases involved and the speed in which Controlled 
Drugs legislation changed in 2018 has left some clinicians, and particularly 
those with a generalist role, feeling that they do not have the specialist 
professional education needed to make fully informed prescribing decisions 
in cases where a CBPM may be appropriate.   
 
52. It will be important for clinicians dealing with cases for which CBPMs may be 
a clinically appropriate treatment option to ensure that they are aware of the 
research and evidence available for a wide range of indications. They also 
need to be prepared to discuss the clinical appropriateness of CBPMs with 
the patient, and/or their parent or carer in an open and consultative manner.  
 
53. We also heard that patient expectation around access to a CBPM is high 
following the rescheduling, and clinicians asked for support to manage this 
expectation.  
 
54. The National Institute for Health and Care Excellence (NICE) was asked by 
the Department of Health and Social Care to produce a clinical guideline on 
the prescribing of cannabis-based products for medicinal use in humans. 
This guidance will be available in October 2019, however NICE has issued a 
draft for consultation.  
 
55. In the interim period, until the NICE Clinical Guideline is finalised, advice was 
commissioned from the specialist medical societies (ABN, BPNA and RCP) 
to support specialist clinicians with their prescribing decisions. This guidance 
was published, alongside the NHS England letter, on the 31st October 2018. 
The NICE clinical guidance will update and replace the interim clinical 
guidance issued by the specialist medical societies.  
 
56. Specialist Clinical Networks are a well-established way of working in 
complex disease areas. These already occur at a regional level and have 
been used to facilitate a second opinion process in this area. Development of 
a UK-wide network will provide both improved specialist care to children and 
provide the basis on which to provide clinical expertise into complex and 
difficult to manage cases.  All clinicians should be able to easily access 
specialist support which will be provided as part of the specialist clinical 
network which we intend to establish.  
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57. On the 3rd July 2019, the Health Select Committee (HSC) published a report 
on medicinal cannabis and recommended that NHS England should issue 
targeted guidance to practitioners and pharmacists explaining the procedure 
for prescribing and supplying cannabis-based products for medicinal use in 
humans. 
 
 
Recommendations:  
 
 
i. A UK-wide paediatric specialist clinical network should be established 
to provide specialist clinical expertise, support discussion of complex 
cases, provide support to clinicians and to assist in evidence 
generation.  
 
ii. The National Medical Director and Chief Pharmaceutical Officer for 
England will write to doctors and pharmacists reminding them of GMC 
guidance on the prescribing and use of unlicensed medicines – and to 
clarify the procedure for prescribing and supplying CBPMs.  Clinicians 
will also be made aware of how they can access the Health Education 
England (HEE) cannabis education package, commissioned by NHS 
England, and published alongside this report. 
 
iii. NHS England and NHS Improvement and the Department of Health and 
Social Care (DHSC) should work together to develop clear information 
for patients and patient groups on the prescribing of cannabis-based 
products for medicinal use.  
 
 
Clinical Evidence  
58. Our review has highlighted that the lack of evidence into the safety and 
effectiveness of CBPMs has weighed heavily on prescribing decisions in 
cases of severe treatment-resistant paediatric epilepsy. In many cases, 
patients have not been considered for or prescribed a CBPM because of the 
lack of high-quality evidence.  
 
59. One of the key themes was the availability of RCT evidence, but there were 
also concerns the evidence would take time to develop.  
 
60. If CBPMs are to be routinely commissioned across the NHS, the science and 
the evidence base supporting use needs to be significantly better developed. 
The NHS needs robust evidence on the effectiveness of CBPMs, as well as 
clear insight into the risk and prevalence of any side effects and must 
approach the issue with care. This will also need a reliable supply of high 
quality, consistent products. 
 
61. The published studies for use of THC-containing products have tended to be 
observational, have lacked a control group and had low patient numbers. 
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These studies are important and can contribute to the evidence base but are 
lower quality sources of evidence compared to RCTs and are not routinely 
used to make population prescribing decisions or recommendations.  
 
62. We heard repeatedly from parents, carers and clinicians that they would 
welcome the availability of RCT evidence, but parents and carers fear this 
would take too long to ensure their child received a CBPM in a timely 
manner.   
 
63. The National Institute for Health Research (NIHR) has issued two calls for 
research proposals to rapidly advance knowledge in this area. The first call 
closed on the 19th March 2019, and the current call closed on 31st July 2019.  
 
64. To further support the generation of new evidence, a detailed and consistent 
set of data on those most affected is needed, including children who are 
currently in receipt of a CBPM.  
 
65. Structured collection of data will add to the underlying evidence base. It can 
also provide information upon which to base RCTs, as already happens in 
normal clinical practice.  
 
66. From the small number of patients with other conditions interviewed, many of 
the same issues – lack of evidence, reluctance to fund and unreliable supply 
– apply. 
 
67. For epilepsy, NICE recommends further research into CBD for severe 
treatment-resistant epilepsy in children, young people and adults, and the 
effect of adding in THC in combination with CBD on seizure frequency, brain 
structure and neurophysiological performance when compared with CBD 
alone.  
 
68. NICE has issued five priority research recommendations in the draft Clinical 
Guideline, which cover the following:  
 
I. CBD as add on treatment for adult patients with Fibromyalgia or 
persistent treatment-resistant neuropathic pain;  
II. CBPMs in Chronic pain in children and young people; 
III. CBPMs for people with spasticity;  
IV. CBD for severe treatment-resistant epilepsy in children, young people 
and adults; and 
V. The effect of adding THC in combination with CBD on seizure 
frequency, brain structure and neurophysiological performance when 
compared with both CBD alone and placebo.  
 
69. For patients who cannot be enrolled into standard RCTs, we need a 
mechanism that will further support the generation of new evidence and that 
draws together a detailed and consistent set of data on the most affected, 
including those children and young adults who are currently in receipt of a 
CBPM. 
 
70. Offering genome sequencing to all children with severe treatment resistant 
epilepsy will allow better data collection and enable a quicker diagnosis 
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which may in the future lead to matching people to the most effective 
medications and interventions and thereby reducing the likelihood of adverse 
drug reactions.   
 
 
Recommendations:  
 
iv. NIHR should support research into the five priority research areas that 
have been identified by the draft NICE clinical guideline on the use of 
cannabis-based products for medicinal use.  
 
v. For severe treatment-resistant paediatric epilepsy, evidence generation 
should be in two forms:  
 
- Support one or more RCTs, using a standardised approach with 
several comparative treatment arms. 
 
- NHS England and NHS Improvement and NIHR in conjunction with the 
specialist network will work together to determine an appropriate 
alternative study design that will enable evidence generation for those 
patients who cannot be enrolled into a standard RCT. This scope of 
study should include those children and young adults who are 
currently in receipt of a CBPM.  
 
xi. These should commence as soon as possible, pending ethical review, 
and if necessary the alternative study should commence in advance of 
the RCT.  
 
vi. NHS England and NHS Improvement, DHSC and Devolved 
Administrations should work with industry and academia to scope the 
development of a national UK patient registry to collect a uniform data 
set, across all indications, for patients prescribed a cannabis-based 
product for medicinal use in the United Kingdom.  
 
vii. NHS England and NHS Improvement will also explore how to update 
the National Genomic Test Directory so that whole genome sequencing 
would be offered to all children with severe treatment-resistant 
epilepsy under consideration for treatment with medical cannabis. 
 
 
Cost and Supply  
71. Clinicians and patients or their carers have highlighted cost and supply of the 
currently available products as a barrier to access.  
 
72. Subject to Marketing Authorisation and outcome of the NICE Technology 
Appraisal, any CBD product or CBPM would be routinely commissioned in 
the usual way for licensed indications.  
 
73. CBPMs by definition are unlicensed and will therefore need to be obtained 
from specialist wholesalers. We understand this process for obtaining 
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CBPMs can be a time-consuming process with import/export forms needing 
to be filled in, often by clinicians or pharmacists. UK-based wholesalers have 
told us that they are unable to guarantee stock as market demand in the UK 
is so uncertain.  Patients should not be expected to travel abroad in order to 
obtain a suitable product as there are lawful routes of supply that can be 
utilised.   
 
74. Concerns were raised by pharmacists around the difficulty in assessing 
quality and consistency of product and they asked for support with this. 
 
 
 
Recommendations:  
 
ix. DHSC and MHRA should work to provide access to information on 
good quality products, manufactured to Good Manufacturing Practice 
standard and with consistent ratios of CBD to THC between batches.  
 
x. NHS England and NHS Improvement should work with suppliers to 
ensure that sufficient stock of good quality CBPMs are available and 
that the products available offer the best value for the NHS, including 
scoping options for UK manufacture.  
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Annex A: Terms of 
Reference  
Cannabis Based Products for Medicinal Use – Process Review 
Aims  
The purpose of the review is to answer the following overarching question: 
Where they exist, what are the barriers to patients accessing cannabis-based 
products for medicinal use within the NHS where they are clinically appropriate for 
the patient and how might these barriers be overcome? 
 
The aims of the process are threefold: 
• to identify the potential barriers to the appropriate prescribing of 
Cannabis Based Products for Medicinal use (CBPMs);   
• to identify any changes that we may want to put in place to support 
appropriate prescriptions of CBPMs in future; and 
• to identify ways in which we might facilitate the building of an evidence 
base for the use of CBPMs.   
Scope  
The review considered indications for which the Association of British Neurologists 
(ABN), the British Paediatric Neurology Association (BPNA) and the Royal College 
of Physicians (RCP) produced interim guidance, however the main focus of the 
review will be on those with an indication of severe treatment-resistant epilepsy.   
The review will be conducted internally and will be based on evidence primarily 
collected through interviews with the Trust personnel involved in the identified cases 
and the patients and/or their carers.  
Out of Scope  
Clinical appropriateness of whether a cannabis-based product for medicinal use is 
suitable for individual patients.  
Methodology  
The review will seek views from patients and/or their carers as well as structured 
interviews with key clinical staff, and other relevant staff within the Trust and/or CCG 
as relevant.   
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Patients who should be involved in the review will be identified by working closely 
with the All-Party Parliamentary Group (APPG) on Medical Cannabis under 
Prescription and through them the patient representative group End Our Pain. The 
patients identified are diagnosed with indications covered by the interim guidance 
produced by the ABN, BPNA and RCP.   
We are reviewing 21 cases in total. We have agreed to include cases from Northern 
Ireland at the request of the Northern Ireland Executive.   
Consent will be obtained from each patient to allow us to conduct the review and to 
allow NHS England and NHS Improvement to speak to the patient’s clinical team 
as part of the process review. 
The following people are expected to be interviewed (as appropriate) for each case 
reviewed:  
- Specialist Clinician  
- Trust Drug and Therapeutics Chair  
- Trust Medical Director and/or Chief Finance Officer  
- Trust Chief Pharmacist  
- NHS England Regional teams or CCG staff  
 
The interview will take the form of structured interviews, which will consider the key 
decision-making points of the prescribing pathway for cannabis-based medicinal 
products that have been identified.  
Based on experience of governance arrangements for prescribing unlicensed 
medicines, it is expected that any potential barriers will arise at these key decision-
making points and our questions will need to investigate and probe these points.  
The interviews will be used to identify and test any barriers to access and the 
potential ways to overcome those barriers.   
Medical Directors at the Trust will be contacted via telephone to inform of them of 
the need for the review and to arrange the interviews. Patients/Carers will also be 
contacted.   
Interviews will take place at the relevant Trust. Patients and/Carers will be invited 
to discuss their experiences either via telephone or at a convenient location.  
Expected Outputs 
The resultant output will be a summary report, including: 
- Potential barriers at each stage of the process from decision to prescribe, to 
supply.  
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- Any other key cross-cutting themes, where they have been identified 
- Potential options for addressing the barriers   
 
The findings and any potential changes will be considered by NHS England.   
Reviewers   
The review is being led by Professor Stephen Powis, National Medical Director, who 
will share the report with Secretary of State for Health for England.  
The interviews will be led and undertaken by Dr Keith Ridge, Chief Pharmaceutical 
Officer, supported by Dr Bruce Warner, Deputy Chief Pharmaceutical Officer, and 
Celia Ingham Clark, Medical Director for Professional Leadership and Clinical 
Effectiveness.  
Secretariat 
The reviewers will be supported by Alexander Williams and Bhavana Reddy, 
Medicines and Diagnostics Policy Unit, in NHS England and NHS Improvement. 
The secretariat will provide policy, analytical and delivery insight to support the 
reviewers.  
Timing 
The review will start in May and will aim to conclude by the end of June. 
Information Governance 
No personalised information will be put into the public domain or released under 
freedom of information unless written content is provided by the patient. 
 
